Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Panbela Therapeutics, Inc. (PBLA)
Company Research
Source: GlobeNewswire
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcaster4.com/Webcast/Page/2556/50531 About Panbela’s PipelineThe pipeline consists of assets currently in clinical trials with an initial focus on familial adenomatous polyposis (FAP), first-line metastatic pancreatic cancer, neoadjuvant pancreatic cancer, colorectal cancer prevention and ovarian can
Show less
Read more
Impact Snapshot
Event Time:
PBLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBLA alerts
High impacting Panbela Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PBLA
News
- Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Panbela Provides Business Update and Reports Q1 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Panbela Provides Business Update and Reports Q1 2024 Financial ResultsGlobeNewswire
- Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacGlobeNewswire
- Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekGlobeNewswire
PBLA
Earnings
- 5/15/24 - Miss
PBLA
Analyst Actions
- 5/16/24 - HC Wainwright
PBLA
Sec Filings
- 5/16/24 - Form 424B3
- 5/16/24 - Form 424B3
- 5/16/24 - Form 424B3
- PBLA's page on the SEC website